Iovance Biotherapeutics Inc IOVA

$7.39 -0.09 (-1.20%)

Valuation

Market cap
3,483,792,000
Revenue TTM
$263,500,000
Net income TTM
$-390,980,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-148.38%
Debt to equity
0.00

Trading

Volume
4,552,046
Avg volume
16,075,158
Day's range
$7.34 – $7.70
Shares out
462,655,000
Stochastic %K
14%
Beta
0.88
Analysts
Strong Buy
Price target
$14.64

Price

Company profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously...

Show more

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
(650) 260-7120
Website
https://www.iovance.com
Address
300 Rouse Blvd., Philadelphia, United States

Latest news

Stocktwits

SlaveLifeAllLife Nov 19, 7:01 PM
$IOVA Looks like all those Jan 2027 will expire worthless. They wait for lung approval to BO this or the very least sBLA.
0 replies
AmericanPulse Nov 19, 6:56 PM
$IOVA In short, Fred Vogt is a lowlife 😂 and loves pizza. Let him finish his meal, then he can look at our situation... The reality is painful, and the stock's movement is giving me a headache, but we've been investors for years and we know this kind of trickery all too well... This is a phase called the "boredom phase" designed to psychologically destroy you, and there are scoundrels like Fred Vogt who just want you to sell so they can buy your shares. Don't let them. Turn off your phone and enjoy your day. I love you
0 replies
AmericanPulse Nov 19, 6:49 PM
$IOVA This is a fantastic opportunity to accumulate shares. Just so you know, don't panic. All indicators are negative, but under no circumstances should you even consider selling at a loss. All your losses are just on paper. Leave it be, and it will surely soar at any moment.
0 replies
tedevan Nov 19, 6:47 PM 0 replies
AmericanPulse Nov 19, 6:46 PM
$IOVA A day will soon come when we will ask you about the date the acquisition of $IOVA is set to be completed—though, personally, I would prefer it not be acquired, as it holds such immense potential ⏳🤌
1 replies
Dorps332 Nov 19, 6:27 PM
$IOVA SLS is at a higher market cap then use with no approved drug and no revenue. Nice
1 replies
Chi_Booth Nov 19, 6:26 PM
$IOVA How is my iova family doing this morning? As for me ...
1 replies
Eugenn33 Nov 19, 6:13 PM
$IOVA I’ve held this for a long time and lived through two major crashes. I’m fucking fed up with how the CEO treats investors—they couldn’t give a shit about us. I’m selling everything and going short—just so that piece-of-shit Fred feels it!
3 replies